Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or
radiation administered for a primary condition, typically a malignant disease, solid organ …

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is
a heterogeneous malignancy characterized by distinct genetic abnormalities. Recent …

Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 inactivation, but
other highly recurrent mutations have not been described. To identify additional driver …

Acute myeloid leukemia (AML) with t (8; 21) or inv (16) have been recognized as unique
entities within AML and are usually reported together as core binding factor AML (CBF …

To clarify the cooperative roles of recurrently identified mutations and to establish a more
precise risk classification system in acute myeloid leukemia (AML), we comprehensively …

To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML)
patients, we examined the gene status for both fusion products such as AML1 (CBF α)–ETO …

The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid
diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic …

The studies concerning clinical implications of TET2 mutation in patients with primary acute
myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults that affects the
myeloid lineage. The recent advances have upgraded our understanding of the cytogenetic …

The associations of mutations in the enhancer of trithorax and polycomb family gene ASXL1
with pretreatment patient characteristics, outcomes, and gene-/microRNA-expression …